Skip to main content
MedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting
September 10, 2021
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
August 31, 2021
Participation terms in the MedinCell Combined General Meeting
August 4, 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
July 28, 2021
MedinCell announces the initiation of coverage of its stock by ODDO-BHF
July 26, 2021
MedinCell announces fiscal year consolidated results April 2020 – March 2021
June 16, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
Videoconference and publication of the results for the 2020-2021 financial year, on June 16, 2021
June 1, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
April 19, 2021
